Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""pharmacokinetics"" wg kryterium: Temat


Tytuł :
Characterization and Validation of Canine P-Glycoprotein-Deficient MDCK II Cell Lines for Efflux Substrate Screening.
Autorzy :
Ye D; Drug Metabolism & Pharmacokinetics-Bioanalytics LU, AbbVie Deutschland GmbH & Co KG, Knollstraße 50, 67061, Ludwigshafen, Germany.
Harder A; Drug Metabolism & Pharmacokinetics-Bioanalytics LU, AbbVie Deutschland GmbH & Co KG, Knollstraße 50, 67061, Ludwigshafen, Germany.; Current Address: Global Marketing and Sales, B. Braun Melsungen AG, Plant P Pfieffewiesen, 34212, Melsungen, Germany.
Fang Z; Drug Metabolism & Pharmacokinetics-Bioanalytics LU, AbbVie Deutschland GmbH & Co KG, Knollstraße 50, 67061, Ludwigshafen, Germany.; Current Address: NCE Drug Metabolism & Pharmacokinetics, Merck Healthcare KGaA, Frankfurter Straße 250, 64293, Darmstadt, Germany.
Weinheimer M; Drug Metabolism & Pharmacokinetics-Bioanalytics LU, AbbVie Deutschland GmbH & Co KG, Knollstraße 50, 67061, Ludwigshafen, Germany.
Laplanche L; Drug Metabolism & Pharmacokinetics-Bioanalytics LU, AbbVie Deutschland GmbH & Co KG, Knollstraße 50, 67061, Ludwigshafen, Germany.
Mezler M; Drug Metabolism & Pharmacokinetics-Bioanalytics LU, AbbVie Deutschland GmbH & Co KG, Knollstraße 50, 67061, Ludwigshafen, Germany. .
Pokaż więcej
Źródło :
Pharmaceutical research [Pharm Res] 2020 Sep 11; Vol. 37 (10), pp. 194. Date of Electronic Publication: 2020 Sep 11.
Typ publikacji :
Journal Article
MeSH Terms :
Pharmacokinetics*
ATP Binding Cassette Transporter, Subfamily B, Member 1/*deficiency
ATP Binding Cassette Transporter, Subfamily G, Member 2/*metabolism
Drug Evaluation, Preclinical/*methods
Neoplasm Proteins/*metabolism
ATP Binding Cassette Transporter, Subfamily B/antagonists & inhibitors ; ATP Binding Cassette Transporter, Subfamily B/genetics ; ATP Binding Cassette Transporter, Subfamily B/metabolism ; ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism ; ATP Binding Cassette Transporter, Subfamily G, Member 2/antagonists & inhibitors ; ATP Binding Cassette Transporter, Subfamily G, Member 2/genetics ; Animals ; Blood-Brain Barrier/metabolism ; Brain/metabolism ; Caco-2 Cells ; Cell Membrane Permeability ; Dibenzocycloheptenes/pharmacology ; Diketopiperazines/pharmacology ; Dogs ; Heterocyclic Compounds, 4 or More Rings/pharmacology ; Humans ; Madin Darby Canine Kidney Cells ; Neoplasm Proteins/antagonists & inhibitors ; Neoplasm Proteins/genetics ; Prazosin/pharmacokinetics ; Quinidine/pharmacokinetics ; Quinolines/pharmacology ; Substrate Specificity ; Transfection
Czasopismo naukowe
Tytuł :
Uptake, accumulation, and translocation mechanisms of steroid estrogens in plants.
Autorzy :
Chen X; State Key Laboratory of Water Environment Simulation, School of Environment, Beijing Normal University, 100875 Beijing, China.
Li Y; State Key Laboratory of Water Environment Simulation, School of Environment, Beijing Normal University, 100875 Beijing, China. Electronic address: .
Jiang L; Beijing University of Agriculture, Beijing 102206, China.
Hu B; State Key Laboratory of Water Environment Simulation, School of Environment, Beijing Normal University, 100875 Beijing, China.
Wang L; State Key Laboratory of Water Environment Simulation, School of Environment, Beijing Normal University, 100875 Beijing, China.
An S; State Key Laboratory of Water Environment Simulation, School of Environment, Beijing Normal University, 100875 Beijing, China.
Zhang X; Beijing Soil and Fertilizer Extension Service Station, Beijing 100029, China.
Pokaż więcej
Źródło :
The Science of the total environment [Sci Total Environ] 2021 Jan 20; Vol. 753, pp. 141979. Date of Electronic Publication: 2020 Aug 25.
Typ publikacji :
Journal Article
MeSH Terms :
Estradiol*/pharmacokinetics
Estrogens*/pharmacokinetics
Plants*
Soil Pollutants*/pharmacokinetics
Adsorption ; Ethinyl Estradiol/pharmacokinetics ; Humans ; Sewage
Czasopismo naukowe
Tytuł :
Pharmacokinetics and anti-inflammatory effects of flunixin meglumine as a sole agent and in combination with phenylbutazone in exercised Thoroughbred horses.
Autorzy :
Knych HK; K.L. Maddy Equine Analytical Pharmacology Laboratory, School of Veterinary Medicine, University of California, Davis, CA, USA.; Department of Veterinary Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, CA, USA.
Arthur RM; School of Veterinary Medicine, University of California, Davis, CA, USA.
McKemie DS; K.L. Maddy Equine Analytical Pharmacology Laboratory, School of Veterinary Medicine, University of California, Davis, CA, USA.
Baden RW; K.L. Maddy Equine Analytical Pharmacology Laboratory, School of Veterinary Medicine, University of California, Davis, CA, USA.
Seminoff K; K.L. Maddy Equine Analytical Pharmacology Laboratory, School of Veterinary Medicine, University of California, Davis, CA, USA.
Kass PH; Department of Population Health and Reproduction, School of Veterinary Medicine, University of California, Davis, CA, USA.
Pokaż więcej
Źródło :
Equine veterinary journal [Equine Vet J] 2021 Jan; Vol. 53 (1), pp. 102-116. Date of Electronic Publication: 2020 Apr 17.
Typ publikacji :
Journal Article; Randomized Controlled Trial, Veterinary
MeSH Terms :
Anti-Inflammatory Agents, Non-Steroidal*/pharmacokinetics
Clonixin*/analogs & derivatives
Clonixin*/pharmacokinetics
Horses/*metabolism
Phenylbutazone/*pharmacokinetics
Animals ; Chromatography, Liquid/veterinary ; Tandem Mass Spectrometry/veterinary
Czasopismo naukowe
Tytuł :
Potent in vitro activity of curcumin and quercetin co-encapsulated in nanovesicles without hyaluronan against Aspergillus and Candida isolates.
Autorzy :
Sadeghi-Ghadi Z; Department of Pharmaceutics, Faculty of Pharmacy, Alborz University of Medical Sciences, Karaj, Iran.
Vaezi A; Department of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Ahangarkani F; Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran; Antimicrobial Resistance Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
Ilkit M; Division of Mycology, Department of Microbiology, Faculty of Medicine, University of Çukurova, Adana, Turkey.
Ebrahimnejad P; Pharmaceutical Science Research Center, hemoglobinopathy institute, Mazandaran University of Medical Sciences, Sari, Iran; Department of Pharmaceutics, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran. Electronic address: .
Badali H; Department of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran; Antimicrobial Resistance Research Center, Mazandaran University of Medical Sciences, Sari, Iran; Fungus Testing Laboratory, Department of Pathology and Laboratory Medicine, University of Texas Health Science Center at San Antonio, San Antonio, USA. Electronic address: .
Pokaż więcej
Źródło :
Journal de mycologie medicale [J Mycol Med] 2020 Dec; Vol. 30 (4), pp. 101014. Date of Electronic Publication: 2020 Jul 25.
Typ publikacji :
Journal Article
MeSH Terms :
Antifungal Agents*/administration & dosage
Antifungal Agents*/pharmacokinetics
Antifungal Agents*/pharmacology
Aspergillus/*drug effects
Candida/*drug effects
Curcumin/*pharmacology
Quercetin/*pharmacology
Curcumin/administration & dosage ; Curcumin/pharmacokinetics ; Drug Combinations ; Drug Compounding/methods ; Drug Delivery Systems ; Drug Resistance, Fungal/drug effects ; Humans ; Hyaluronic Acid/chemistry ; Microbial Sensitivity Tests ; Nanocapsules/administration & dosage ; Nanocapsules/chemistry ; Quercetin/administration & dosage ; Quercetin/pharmacokinetics ; Skin/drug effects ; Skin/metabolism ; Skin Absorption
Czasopismo naukowe
Tytuł :
pH-bioresponsive poly(ε-caprolactone)-based polymersome for effective drug delivery in cancer and protein glycoxidation prevention.
Autorzy :
Ghorbanizamani F; Biochemistry Department, Faculty of Science, Ege University, Bornova, Izmir, 35100, Turkey.
Moulahoum H; Biochemistry Department, Faculty of Science, Ege University, Bornova, Izmir, 35100, Turkey. Electronic address: .
Sanli S; Biochemistry Department, Faculty of Science, Ege University, Bornova, Izmir, 35100, Turkey.
Bayir E; Central Research Testing and Analysis Laboratory Research and Application Center, Ege University, Bornova, Izmir, 35100, Turkey.
Zihnioglu F; Biochemistry Department, Faculty of Science, Ege University, Bornova, Izmir, 35100, Turkey.
Timur S; Biochemistry Department, Faculty of Science, Ege University, Bornova, Izmir, 35100, Turkey; Central Research Testing and Analysis Laboratory Research and Application Center, Ege University, Bornova, Izmir, 35100, Turkey. Electronic address: .
Pokaż więcej
Źródło :
Archives of biochemistry and biophysics [Arch Biochem Biophys] 2020 Nov 30; Vol. 695, pp. 108643. Date of Electronic Publication: 2020 Oct 22.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Carriers*/chemistry
Drug Carriers*/pharmacokinetics
Drug Carriers*/pharmacology
Glutathione*/chemistry
Glutathione*/pharmacokinetics
Glutathione*/pharmacology
Neoplasms*/drug therapy
Neoplasms*/metabolism
Neoplasms*/pathology
Polyesters*/chemistry
Polyesters*/pharmacokinetics
Polyesters*/pharmacology
Neoplasm Proteins/*metabolism
Animals ; Chlorocebus aethiops ; Delayed-Action Preparations/chemistry ; Delayed-Action Preparations/pharmacokinetics ; Delayed-Action Preparations/pharmacology ; Glycosylation/drug effects ; HeLa Cells ; Humans ; Hydrogen-Ion Concentration ; Vero Cells
Czasopismo naukowe
Tytuł :
Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A.
Autorzy :
Solms A; Clinical Pharmacometrics, Pharmaceuticals Research & Development, Bayer AG, 13353, Berlin, Germany. .
Shah A; Bayer, Whippany, NJ, USA.
Berntorp E; Centre for Thrombosis and Haemostasis, Lund University, Skåne University Hospital, Malmö, Sweden.
Tiede A; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hanover, Germany.
Iorio A; McMaster-Bayer Endowed Research Chair in Clinical Epidemiology of Congenital Bleeding Disorders, Department of Medicine, McMaster University, Hamilton, Canada.; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada.
Linardi C; Bayer, Whippany, NJ, USA.
Ahsman M; LAP&P Consultants BV, Leiden, the Netherlands.
Mancuso ME; Center for Thrombosis and Hemorrhagic Diseases, Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy.
Zhivkov T; Specialized Hospital for Active Treatment, Sofia, Bulgaria.
Lissitchkov T; Specialized Hospital for Active Treatment, Sofia, Bulgaria.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2020 Nov; Vol. 99 (11), pp. 2689-2698. Date of Electronic Publication: 2020 Sep 24.
Typ publikacji :
Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
MeSH Terms :
Factor VIII*/administration & dosage
Factor VIII*/pharmacokinetics
Hemophilia A*/blood
Hemophilia A*/drug therapy
Adolescent ; Adult ; Aged ; Cross-Over Studies ; Half-Life ; Humans ; Male ; Middle Aged ; Polyethylene Glycols ; Recombinant Proteins/administration & dosage ; Recombinant Proteins/pharmacokinetics
Czasopismo naukowe
Tytuł :
QT Interval Prolongation Under Hydroxychloroquine/Azithromycin Association for Inpatients With SARS-CoV-2 Lower Respiratory Tract Infection.
Autorzy :
Bun SS; Cardiology Department, Pasteur University Hospital, Nice, France.
Taghji P; Cardiology Department, Clinique la Casamance, Aubagne, France.
Courjon J; Infectious Diseases Department, Archet University Hospital, Nice, France.
Squara F; Cardiology Department, Pasteur University Hospital, Nice, France.
Scarlatti D; Cardiology Department, Pasteur University Hospital, Nice, France.
Theodore G; Cardiology Department, Pasteur University Hospital, Nice, France.
Baudouy D; Cardiology Department, Pasteur University Hospital, Nice, France.
Sartre B; Cardiology Department, Pasteur University Hospital, Nice, France.
Labbaoui M; Cardiology Department, Pasteur University Hospital, Nice, France.
Dellamonica J; Medical Intensive Care Unit, Archet University Hospital, Nice, France.
Doyen D; Medical Intensive Care Unit, Archet University Hospital, Nice, France.
Marquette CH; Department of Respiratory Medicine, Pasteur University Hospital, Nice, France.
Levraut J; Department of Emergency Medicine, Pasteur University Hospital, Nice, France.
Esnault V; Nephrology Department, Pasteur University Hospital, Nice, France.
Bun SS; Pharmacy Faculty, CNRS, IRD, IMBE, Aix Marseille University, Marseille, France.; Pharmacy Department, CHU Nord, APHM, Marseille, France.
Ferrari E; Cardiology Department, Pasteur University Hospital, Nice, France.
Pokaż więcej
Źródło :
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2020 Nov; Vol. 108 (5), pp. 1090-1097. Date of Electronic Publication: 2020 Jul 20.
Typ publikacji :
Journal Article
MeSH Terms :
Azithromycin*/administration & dosage
Azithromycin*/adverse effects
Azithromycin*/pharmacokinetics
Coronavirus Infections*/diagnosis
Coronavirus Infections*/drug therapy
Coronavirus Infections*/physiopathology
Drug Monitoring*/instrumentation
Drug Monitoring*/methods
Drug Monitoring*/standards
Hydroxychloroquine*/administration & dosage
Hydroxychloroquine*/adverse effects
Hydroxychloroquine*/pharmacokinetics
Long QT Syndrome*/chemically induced
Long QT Syndrome*/diagnosis
Pandemics*
Electrocardiography/*methods
Pneumonia, Viral/*drug therapy
Anti-Infective Agents/administration & dosage ; Anti-Infective Agents/adverse effects ; Anti-Infective Agents/pharmacokinetics ; Betacoronavirus/isolation & purification ; COVID-19 ; Dimensional Measurement Accuracy ; Female ; Humans ; Male ; Middle Aged ; Outcome Assessment, Health Care ; Pneumonia, Viral/diagnosis ; Pneumonia, Viral/physiopathology ; SARS-CoV-2 ; Torsades de Pointes/chemically induced ; Torsades de Pointes/prevention & control
SCR Protocol :
COVID-19 drug treatment
Czasopismo naukowe
Tytuł :
Pharmacokinetic variability of beta-lactams in critically ill patients: A narrative review.
Autorzy :
Boidin C; Hospices Civils de Lyon, Groupement Hospitalier Nord, Hôpital Pierre Garraud, Service pharmacie, 136, rue du Commandant Charcot, 69005 Lyon, France; Univ Lyon, Université Claude Bernard Lyon 1, UMR CNRS 5558, Laboratoire de Biométrie et Biologie Évolutive, Bât. Grégor Mendel, 43, boulevard du 11 novembre 1918, 69622 Villeurbanne Cedex, France. Electronic address: .
Moshiri P; CHR d'Orléans, Laboratoire de Biochimie, 14, avenue de l'hôpital, 45100 Orléans, France. Electronic address: .
Dahyot-Fizelier C; CHU de Poitiers, Service d'Anesthésie-Réanimation, 2, rue de la Milétrie, 86021 Poitiers, France; Université de Poitiers, UMR 1070, 6, rue de la Milétrie, 86073 Poitiers, France. Electronic address: .
Goutelle S; Hospices Civils de Lyon, Groupement Hospitalier Nord, Hôpital Pierre Garraud, Service pharmacie, 136, rue du Commandant Charcot, 69005 Lyon, France; Univ Lyon, Université Claude Bernard Lyon 1, UMR CNRS 5558, Laboratoire de Biométrie et Biologie Évolutive, Bât. Grégor Mendel, 43, boulevard du 11 novembre 1918, 69622 Villeurbanne Cedex, France; Univ Lyon, Université Claude Bernard Lyon 1, ISPB - Faculté de Pharmacie de Lyon, 8, avenue Rockefeller, 69008 Lyon, France. Electronic address: .
Lefeuvre S; CHR d'Orléans, Laboratoire de Biochimie, 14, avenue de l'hôpital, 45100 Orléans, France. Electronic address: .
Pokaż więcej
Źródło :
Anaesthesia, critical care & pain medicine [Anaesth Crit Care Pain Med] 2020 Feb; Vol. 39 (1), pp. 87-109. Date of Electronic Publication: 2019 Sep 09.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Critical Illness*
Pharmacokinetics*
Anti-Bacterial Agents/*pharmacokinetics
beta-Lactams/*pharmacokinetics
Critical Care/methods ; Drug Monitoring ; Humans
Czasopismo naukowe
Tytuł :
Optimization and evaluation of propolis liposomes as a promising therapeutic approach for COVID-19.
Autorzy :
Refaat H; Department of Pharmaceutics, Faculty of Pharmacy, Deraya University, Minia, Egypt.
Mady FM; Department of Pharmaceutics, Faculty of Pharmacy, Minia University, Minia, Egypt.
Sarhan HA; Department of Pharmaceutics, Faculty of Pharmacy, Minia University, Minia, Egypt.
Rateb HS; Department of Pharmaceutical Chemistry, College of Pharmaceutical Science and Drug Manufacturing, Misr University for Science and Technology, Cairo, Egypt.
Alaaeldin E; Department of Pharmaceutics, Faculty of Pharmacy, Deraya University, Minia, Egypt; Department of Pharmaceutics, Faculty of Pharmacy, Minia University, Minia, Egypt. Electronic address: .
Pokaż więcej
Źródło :
International journal of pharmaceutics [Int J Pharm] 2021 Jan 05; Vol. 592, pp. 120028. Date of Electronic Publication: 2020 Nov 07.
Typ publikacji :
Journal Article
MeSH Terms :
Propolis*/administration & dosage
Propolis*/pharmacokinetics
SARS-CoV-2*/drug effects
SARS-CoV-2*/isolation & purification
SARS-CoV-2*/physiology
COVID-19/*drug therapy
Virus Replication/*drug effects
Antiviral Agents/administration & dosage ; COVID-19/metabolism ; COVID-19/virology ; COVID-19 Nucleic Acid Testing ; Coronavirus 3C Proteases/metabolism ; Flavonoids/pharmacokinetics ; Humans ; Liposomes ; Molecular Docking Simulation/methods ; Outcome Assessment, Health Care ; Spike Glycoprotein, Coronavirus/metabolism
Czasopismo naukowe
Tytuł :
Dalbavancin binds ACE2 to block its interaction with SARS-CoV-2 spike protein and is effective in inhibiting SARS-CoV-2 infection in animal models.
Autorzy :
Wang G; Key Laboratory of Animal Models and Human Disease Mechanisms, Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, National Resource Center for Non-Human Primates, Kunming Primate Research Center, and National Research Facility for Phenotypic & Genetic Analysis of Model Animals (Primate Facility), Kunming Institute of Zoology, Kunming, Yunnan, 650107, China.
Yang ML; Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, Yunnan, 650031, China.
Duan ZL; Key Laboratory of Animal Models and Human Disease Mechanisms, Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, National Resource Center for Non-Human Primates, Kunming Primate Research Center, and National Research Facility for Phenotypic & Genetic Analysis of Model Animals (Primate Facility), Kunming Institute of Zoology, Kunming, Yunnan, 650107, China.
Liu FL; Key Laboratory of Animal Models and Human Disease Mechanisms, Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, National Resource Center for Non-Human Primates, Kunming Primate Research Center, and National Research Facility for Phenotypic & Genetic Analysis of Model Animals (Primate Facility), Kunming Institute of Zoology, Kunming, Yunnan, 650107, China.
Jin L; Key Laboratory of Animal Models and Human Disease Mechanisms, Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, National Resource Center for Non-Human Primates, Kunming Primate Research Center, and National Research Facility for Phenotypic & Genetic Analysis of Model Animals (Primate Facility), Kunming Institute of Zoology, Kunming, Yunnan, 650107, China.
Long CB; Key Laboratory of Animal Models and Human Disease Mechanisms, Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, National Resource Center for Non-Human Primates, Kunming Primate Research Center, and National Research Facility for Phenotypic & Genetic Analysis of Model Animals (Primate Facility), Kunming Institute of Zoology, Kunming, Yunnan, 650107, China.
Zhang M; Key Laboratory of Animal Models and Human Disease Mechanisms, Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, National Resource Center for Non-Human Primates, Kunming Primate Research Center, and National Research Facility for Phenotypic & Genetic Analysis of Model Animals (Primate Facility), Kunming Institute of Zoology, Kunming, Yunnan, 650107, China.; University of Chinese Academy of Sciences, Beijing, 100049, China.
Tang XP; Key Laboratory of Animal Models and Human Disease Mechanisms, Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, National Resource Center for Non-Human Primates, Kunming Primate Research Center, and National Research Facility for Phenotypic & Genetic Analysis of Model Animals (Primate Facility), Kunming Institute of Zoology, Kunming, Yunnan, 650107, China.; Sino-African Joint Research Center, Chinese Academy of Science, Wuhan, Hubei, 430074, China.
Xu L; Key Laboratory of Animal Models and Human Disease Mechanisms, Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, National Resource Center for Non-Human Primates, Kunming Primate Research Center, and National Research Facility for Phenotypic & Genetic Analysis of Model Animals (Primate Facility), Kunming Institute of Zoology, Kunming, Yunnan, 650107, China.
Li YC; Key Laboratory of Animal Models and Human Disease Mechanisms, Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, National Resource Center for Non-Human Primates, Kunming Primate Research Center, and National Research Facility for Phenotypic & Genetic Analysis of Model Animals (Primate Facility), Kunming Institute of Zoology, Kunming, Yunnan, 650107, China.
Kamau PM; Key Laboratory of Animal Models and Human Disease Mechanisms, Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, National Resource Center for Non-Human Primates, Kunming Primate Research Center, and National Research Facility for Phenotypic & Genetic Analysis of Model Animals (Primate Facility), Kunming Institute of Zoology, Kunming, Yunnan, 650107, China.; University of Chinese Academy of Sciences, Beijing, 100049, China.; Sino-African Joint Research Center, Chinese Academy of Science, Wuhan, Hubei, 430074, China.
Yang L; Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, Yunnan, 650201, China.
Liu HQ; Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, Yunnan, 650031, China.
Xu JW; Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, Yunnan, 650031, China.
Chen JK; Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, Guangdong, 510530, China.
Zheng YT; Key Laboratory of Animal Models and Human Disease Mechanisms, Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, National Resource Center for Non-Human Primates, Kunming Primate Research Center, and National Research Facility for Phenotypic & Genetic Analysis of Model Animals (Primate Facility), Kunming Institute of Zoology, Kunming, Yunnan, 650107, China. .; Kunming National High-level Biosafety Research Center for Non-human Primates, Center for Biosafety Mega-Science, Kunming Institute of Zoology Chinese Academic of Sciences, Kunming, Yunnan, 650107, China. .
Peng XZ; Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, Yunnan, 650031, China. .
Lai R; Key Laboratory of Animal Models and Human Disease Mechanisms, Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, National Resource Center for Non-Human Primates, Kunming Primate Research Center, and National Research Facility for Phenotypic & Genetic Analysis of Model Animals (Primate Facility), Kunming Institute of Zoology, Kunming, Yunnan, 650107, China. .; Sino-African Joint Research Center, Chinese Academy of Science, Wuhan, Hubei, 430074, China. .; Kunming National High-level Biosafety Research Center for Non-human Primates, Center for Biosafety Mega-Science, Kunming Institute of Zoology Chinese Academic of Sciences, Kunming, Yunnan, 650107, China. .; Institutes for Drug Discovery and Development, Chinese Academy of Sciences, Shanghai, 201203, China. .
Pokaż więcej
Źródło :
Cell research [Cell Res] 2021 Jan; Vol. 31 (1), pp. 17-24. Date of Electronic Publication: 2020 Dec 01.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antiviral Agents*/pharmacokinetics
Antiviral Agents*/pharmacology
Angiotensin-Converting Enzyme 2/*metabolism
SARS-CoV-2/*metabolism
Spike Glycoprotein, Coronavirus/*metabolism
Teicoplanin/*analogs & derivatives
Animals ; Caco-2 Cells ; Chlorocebus aethiops ; Disease Models, Animal ; Humans ; Mice ; Mice, Transgenic ; Protein Binding/drug effects ; Teicoplanin/pharmacokinetics ; Teicoplanin/pharmacology ; Vero Cells
Czasopismo naukowe
Tytuł :
Mechanisms of increased bioavailability through amorphous solid dispersions: a review.
Autorzy :
Schittny A; Department of Pharmaceutical Sciences, Division of Pharmaceutical Technology, University of Basel, Basel, Switzerland.; Department of Biomedicine, Division of Clinical Pharmacology and Toxicology, University Hospital Basel and University of Basel, Basel, Switzerland.
Huwyler J; Department of Pharmaceutical Sciences, Division of Pharmaceutical Technology, University of Basel, Basel, Switzerland.
Puchkov M; Department of Pharmaceutical Sciences, Division of Pharmaceutical Technology, University of Basel, Basel, Switzerland.
Pokaż więcej
Źródło :
Drug delivery [Drug Deliv] 2020 Dec; Vol. 27 (1), pp. 110-127.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Pharmacokinetics*
Excipients/*chemistry
Technology, Pharmaceutical/*methods
Biological Availability ; Crystallization ; Delayed-Action Preparations ; Drug Liberation ; Drug Stability ; Solubility ; Surface-Active Agents/chemistry
Czasopismo naukowe
Tytuł :
CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial.
Autorzy :
Gutierrez JA; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC; Division of Cardiology, Duke University School of Medicine, Durham, NC. Electronic address: .
Heizer GM; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.
Jones WS; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC; Division of Cardiology, Duke University School of Medicine, Durham, NC.
Rockhold FW; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.
Mahaffey KW; Stanford Center for Clinical Research, Stanford University School of Medicine, Stanford, CA.
Fowkes FGR; Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.
Berger JS; Departments of Medicine and Surgery, New York University School of Medicine, New York, NY.
Baumgartner I; Swiss Cardiovascular Centre, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Held P; University of Gothenburg, Sweden.
Katona BG; AstraZeneca Gaithersburg, Gaithersburg, MD.
Norgren L; Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Blomster JI; Turku University Hospital, Turku, Finland.
Hiatt WR; University of Colorado School of Medicine and CPC Clinical Research, Aurora, CO.
Patel MR; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC; Division of Cardiology, Duke University School of Medicine, Durham, NC.
Pokaż więcej
Źródło :
American heart journal [Am Heart J] 2020 Nov; Vol. 229, pp. 118-120. Date of Electronic Publication: 2020 Aug 16.
Typ publikacji :
Letter; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Cardiovascular Diseases*/diagnosis
Cardiovascular Diseases*/etiology
Cardiovascular Diseases*/mortality
Cardiovascular Diseases*/surgery
Clopidogrel*/administration & dosage
Clopidogrel*/adverse effects
Clopidogrel*/pharmacokinetics
Hemorrhage*/chemically induced
Hemorrhage*/diagnosis
Ischemia*/etiology
Ischemia*/surgery
Peripheral Arterial Disease*/complications
Peripheral Arterial Disease*/drug therapy
Peripheral Arterial Disease*/genetics
Vascular Surgical Procedures*/methods
Vascular Surgical Procedures*/statistics & numerical data
Cytochrome P-450 CYP2C19/*genetics
Extremities/blood supply ; Female ; Humans ; Loss of Function Mutation ; Male ; Middle Aged ; Outcome and Process Assessment, Health Care ; Pharmacogenomic Testing/methods ; Platelet Aggregation Inhibitors/administration & dosage ; Platelet Aggregation Inhibitors/adverse effects ; Platelet Aggregation Inhibitors/pharmacokinetics
Raport
Tytuł :
The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.
Autorzy :
Manley PW; Novartis Institutes for Biomedical Research, Novartis Pharma AG, CH-4002 Basel, Switzerland. Electronic address: .
Barys L; Novartis Institutes for Biomedical Research, Novartis Pharma AG, CH-4002 Basel, Switzerland.
Cowan-Jacob SW; Novartis Institutes for Biomedical Research, Novartis Pharma AG, CH-4002 Basel, Switzerland.
Pokaż więcej
Źródło :
Leukemia research [Leuk Res] 2020 Nov; Vol. 98, pp. 106458. Date of Electronic Publication: 2020 Sep 29.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Fusion Proteins, bcr-abl*/antagonists & inhibitors
Fusion Proteins, bcr-abl*/genetics
Fusion Proteins, bcr-abl*/metabolism
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/enzymology
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/pathology
Mutation*
Pyrazoles*/pharmacokinetics
Pyrazoles*/therapeutic use
Cell Proliferation/*drug effects
Drug Resistance, Neoplasm/*drug effects
Niacinamide/*analogs & derivatives
Binding Sites ; Drug Resistance, Neoplasm/genetics ; Humans ; Niacinamide/pharmacokinetics ; Niacinamide/therapeutic use
Czasopismo naukowe
Tytuł :
Quantitative prediction of human pharmacokinetic responses to drugs via fluidically coupled vascularized organ chips.
Autorzy :
Herland A; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA.; Division of Micro and Nanosystems, KTH Royal Institute of Technology, Stockholm, Sweden.; AIMES, Department of Neuroscience, Karolinska Institute, Stockholm, Sweden.
Maoz BM; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA.; Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, USA.; Department of Biomedical Engineering, Tel Aviv University, Tel Aviv, Israel.; Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.
Das D; CFD Research Corporation, Huntsville, AL, USA.
Somayaji MR; CFD Research Corporation, Huntsville, AL, USA.
Prantil-Baun R; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA.
Novak R; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA.
Cronce M; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA.
Huffstater T; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA.
Jeanty SSF; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA.
Ingram M; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA.
Chalkiadaki A; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA.
Benson Chou D; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA.
Marquez S; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA.
Delahanty A; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA.
Jalili-Firoozinezhad S; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA.; Department of Bioengineering and Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Portugal Graduate Program, Universidade de Lisboa, Lisbon, Portugal.
Milton Y; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA.
Sontheimer-Phelps A; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA.; Faculty of Biology, University of Freiburg, Freiburg, Germany.
Swenor B; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA.
Levy O; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA.
Parker KK; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA.; Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, USA.
Przekwas A; CFD Research Corporation, Huntsville, AL, USA.
Ingber DE; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA. .; Division of Micro and Nanosystems, KTH Royal Institute of Technology, Stockholm, Sweden. .; Vascular Biology Program and Department of Surgery, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA. .
Pokaż więcej
Źródło :
Nature biomedical engineering [Nat Biomed Eng] 2020 Apr; Vol. 4 (4), pp. 421-436. Date of Electronic Publication: 2020 Jan 27.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Lab-On-A-Chip Devices*
Pharmaceutical Preparations*/administration & dosage
Pharmaceutical Preparations*/metabolism
Pharmacokinetics*
Microfluidics/*methods
Animals ; Cisplatin/pharmacokinetics ; Drug Design ; Humans ; In Vitro Techniques ; Liver/metabolism ; Microfluidics/instrumentation ; Models, Biological ; Nicotine/pharmacokinetics
Czasopismo naukowe
Tytuł :
Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial.
Autorzy :
Lou Y; State Key Laboratory for diagnosis and treatment of infectious diseases, Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Liu L; State Key Laboratory for diagnosis and treatment of infectious diseases, Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Yao H; State Key Laboratory for diagnosis and treatment of infectious diseases, Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Hu X; State Key Laboratory for diagnosis and treatment of infectious diseases, Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Su J; State Key Laboratory for diagnosis and treatment of infectious diseases, Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Xu K; State Key Laboratory for diagnosis and treatment of infectious diseases, Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Luo R; State Key Laboratory for diagnosis and treatment of infectious diseases, Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Yang X; State Key Laboratory for diagnosis and treatment of infectious diseases, Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
He L; State Key Laboratory for diagnosis and treatment of infectious diseases, Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Lu X; State Key Laboratory for diagnosis and treatment of infectious diseases, Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Zhao Q; State Key Laboratory for diagnosis and treatment of infectious diseases, Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Liang T; State Key Laboratory for diagnosis and treatment of infectious diseases, Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Qiu Y; State Key Laboratory for diagnosis and treatment of infectious diseases, Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China. Electronic address: .
Pokaż więcej
Źródło :
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences [Eur J Pharm Sci] 2021 Feb 01; Vol. 157, pp. 105631. Date of Electronic Publication: 2020 Oct 25.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Amides*/administration & dosage
Amides*/blood
Amides*/pharmacokinetics
COVID-19*/blood
COVID-19*/diagnosis
COVID-19*/drug therapy
COVID-19*/physiopathology
Dibenzothiepins*/administration & dosage
Dibenzothiepins*/blood
Dibenzothiepins*/pharmacokinetics
Morpholines*/administration & dosage
Morpholines*/blood
Morpholines*/pharmacokinetics
Pyrazines*/administration & dosage
Pyrazines*/blood
Pyrazines*/pharmacokinetics
Pyridones*/administration & dosage
Pyridones*/blood
Pyridones*/pharmacokinetics
Triazines*/administration & dosage
Triazines*/blood
Triazines*/pharmacokinetics
Antiviral Agents/administration & dosage ; Antiviral Agents/blood ; Antiviral Agents/pharmacokinetics ; Drug Monitoring/methods ; Female ; Humans ; Inhibitory Concentration 50 ; Male ; Middle Aged ; SARS-CoV-2/drug effects ; SARS-CoV-2/isolation & purification ; SARS-CoV-2/physiology ; Symptom Assessment ; Treatment Outcome ; Viral Load/drug effects
Czasopismo naukowe
Tytuł :
Pharmacokinetics and safety after once and twice a day doses of meclizine hydrochloride administered to children with achondroplasia.
Autorzy :
Kitoh H; Department of Orthopaedic Surgery, Aichi Children's Health and Medical Center, Obu, Aichi, Japan.; Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Aichi, Japan.
Matsushita M; Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Aichi, Japan.
Mishima K; Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Aichi, Japan.
Nagata T; Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Aichi, Japan.
Kamiya Y; Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Aichi, Japan.
Ueda K; Department of Advanced Medicine, Nagoya University Hospital, Showa-ku, Nagoya, Aichi, Japan.
Kuwatsuka Y; Department of Advanced Medicine, Nagoya University Hospital, Showa-ku, Nagoya, Aichi, Japan.
Morikawa H; Ina Research Inc, Ina, Nagano, Japan.
Nakai Y; Department of Advanced Medicine, Nagoya University Hospital, Showa-ku, Nagoya, Aichi, Japan.
Ishiguro N; Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Aichi, Japan.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2020 Apr 13; Vol. 15 (4), pp. e0229639. Date of Electronic Publication: 2020 Apr 13 (Print Publication: 2020).
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Pharmacokinetics*
Achondroplasia/*drug therapy
Meclizine/*administration & dosage
Meclizine/*pharmacokinetics
Achondroplasia/blood ; Achondroplasia/pathology ; Administration, Oral ; Animals ; Child ; Child, Preschool ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Humans ; Male ; Meclizine/blood ; Mice
Czasopismo naukowe
Tytuł :
Positron emission tomography studies of organophosphate chemical threats and oxime countermeasures.
Autorzy :
Thompson CM; Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT 59812, USA. Electronic address: .
Gerdes JM; Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT 59812, USA.
VanBrocklin HF; Department of Radiology and Biomedical Imaging, University of California, San Francisco 185 Berry St. Suite 350, San Francisco, CA 94107, USA.
Pokaż więcej
Źródło :
Neurobiology of disease [Neurobiol Dis] 2020 Jan; Vol. 133, pp. 104455. Date of Electronic Publication: 2019 Apr 22.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Review
MeSH Terms :
Nerve Agents*/pharmacokinetics
Nerve Agents*/toxicity
Organophosphorus Compounds*/pharmacokinetics
Organophosphorus Compounds*/toxicity
Radiopharmaceuticals*
Cholinesterase Reactivators/*pharmacokinetics
Positron-Emission Tomography/*methods
Animals ; Antidotes/pharmacokinetics ; Humans ; Oximes/pharmacokinetics
Czasopismo naukowe
Tytuł :
Overcoming the paracetamol dose challenge with wrinkled mesoporous carbon spheres.
Autorzy :
Goscianska J; Adam Mickiewicz University in Poznań, Faculty of Chemistry, Uniwersytetu Poznańskiego 8, 61-614 Poznań, Poland. Electronic address: .
Olejnik A; Adam Mickiewicz University in Poznań, Faculty of Chemistry, Uniwersytetu Poznańskiego 8, 61-614 Poznań, Poland.
Ejsmont A; Adam Mickiewicz University in Poznań, Faculty of Chemistry, Uniwersytetu Poznańskiego 8, 61-614 Poznań, Poland.
Galarda A; Adam Mickiewicz University in Poznań, Faculty of Chemistry, Uniwersytetu Poznańskiego 8, 61-614 Poznań, Poland.
Wuttke S; BCMaterials, Basque Center for Materials, UPV/EHU Science Park, 48940 Leioa, Spain; Ikerbasque, Basque Foundation for Science, 48013 Bilbao, Spain. Electronic address: .
Pokaż więcej
Źródło :
Journal of colloid and interface science [J Colloid Interface Sci] 2021 Mar 15; Vol. 586, pp. 673-682. Date of Electronic Publication: 2020 Nov 13.
Typ publikacji :
Journal Article
MeSH Terms :
Acetaminophen*/chemistry
Acetaminophen*/pharmacokinetics
Drug Carriers*/chemistry
Drug Carriers*/pharmacokinetics
SARS-CoV-2*
COVID-19/*drug therapy
Carbon/*chemistry
Pain/*drug therapy
Delayed-Action Preparations/chemistry ; Delayed-Action Preparations/pharmacokinetics ; Humans
Czasopismo naukowe
Tytuł :
In vitro Pharmacokinetic Cell Culture System that Simulates Physiologic Drug and Nanoparticle Exposure to Macrophages.
Autorzy :
Kutscher HL; Translational Pharmacology Research Core, NYS Center of Excellence in Bioinformatics and Life Sciences, University at Buffalo, Buffalo, New York, 14203, USA.; Institute for Lasers, Photonics and Biophotonics, University at Buffalo, Buffalo, New York, 14260, USA.; Department of Anesthesiology, University at Buffalo, Buffalo, New York, 14203, USA.
Morse GD; Translational Pharmacology Research Core, NYS Center of Excellence in Bioinformatics and Life Sciences, University at Buffalo, Buffalo, New York, 14203, USA.; Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, 14214, USA.
Prasad PN; Institute for Lasers, Photonics and Biophotonics, University at Buffalo, Buffalo, New York, 14260, USA.
Reynolds JL; Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, 14203, USA. .
Pokaż więcej
Źródło :
Pharmaceutical research [Pharm Res] 2019 Feb 01; Vol. 36 (3), pp. 44. Date of Electronic Publication: 2019 Feb 01.
Typ publikacji :
Journal Article
MeSH Terms :
Pharmacokinetics*
Cell Culture Techniques/*methods
Drug Carriers/*pharmacokinetics
Macrophages/*drug effects
Macrophages/*metabolism
Nanoparticles/*administration & dosage
Nanoparticles/*metabolism
Anti-Bacterial Agents/administration & dosage ; Anti-Bacterial Agents/pharmacokinetics ; Cell Culture Techniques/instrumentation ; Cell Line ; Drug Carriers/administration & dosage ; Drug Delivery Systems ; Humans ; Nanoparticles/chemistry ; Rifampin/administration & dosage ; Rifampin/pharmacokinetics
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies